David Berman, M.D., Ph.D.

Chief Development Officer

As Chief Development Officer, David Berman, M.D., Ph.D., leads Moderna’s development organization.



Dr. Berman brings more than two decades of experience advancing immunotherapies across oncology and infectious disease. He has worked on more than a dozen clinical-stage programs and held senior leadership roles in the development of four globally approved oncology biologics. Most recently, he served as Executive Vice President and Head of Research and Development at Immunocore, where he led the development and approval of the first T cell receptor therapeutic. Prior to Immunocore, Dr. Berman was Senior Vice President and Head of AstraZeneca’s Immuno-oncology franchise. He also held senior development roles at Bristol-Myers Squibb, including Global Clinical Lead for the first approved immune checkpoint inhibitor.

Dr. Berman earned his M.D. and Ph.D. from the University of Texas Southwestern Medical School. He completed his pathology training at the National Cancer Institute and a fellowship at The Johns Hopkins Hospital.